Recognized expert in pharmaceutical pricing and access with a career spanning global economic affairs, value strategy, and executive advisory roles. Experienced in building high-impact pricing and reimbursement organizations and guiding major pharmaceutical companies through evidence generation, payer negotiations, and global launch planning. Longstanding contributor to industry thought leadership through publications, expert testimony, and board service for research-driven nonprofits. Work emphasizes strategic clarity, global perspective, and rigorous evidence-based decision support.

Biopharmaceutical pricing and market access expert with extensive leadership experience across global pharmaceutical companies and consulting organizations. Advisor to executives and boards on pricing strategy, value demonstration, payer evidence development, and reimbursement negotiations. Published author and recognized thought leader in global drug pricing.

• Deep expertise in global pricing, reimbursement, and market access strategy

• Proven leadership building and scaling economic affairs and value organizations

• Extensive experience advising executives, boards, and global biopharma teams

• Strong record of shaping pricing policy, payer evidence strategy, and access negotiations

• Thought leadership through publications, expert witness engagements, and industry contributions

• Ability to translate complex value narratives into compelling payer communications

• Global perspective grounded in consulting, corporate leadership, and nonprofit board service

• Pharmaceutical pricing frameworks and access models

• Global payer systems and reimbursement pathways

• Health economics and outcomes research methodologies

• Value demonstration tools and evidence development strategies

• Pricing and access negotiation processes

• Formulary and payer communications development

• Commercial strategy and product lifecycle valuation

• Advisor/Coach, Consulting Advisory, LLC | Jan 2024 – Present

• Principal Advisor (Part-Time Contract), ZS Associates | Jan 2024 – Present

• Managing Partner, Value & Access Practice, ZS Associates | Apr 2009 – Dec 2023

• Board Member, BrightFocus Foundation | Jun 2007 – Jun 2019

• Board Member, Internationale Stichting Alzheimer Onderzoek | Oct 2011 – Feb 2015

• Vice-President, Global Pricing and Reimbursement, Bristol-Myers Squibb | Jun 2005 – Mar 2009

• President, Schoonveld Access Consulting | Sep 2004 – Jun 2005

• EVP & General Manager, Pricing & Market Access, The Analytica Group | Oct 2002 – Sep 2004

• EVP, Cambridge Pharma Consultancy | Jan 2001 – Oct 2002

• Director, Global Economic Affairs, Eli Lilly & Company | Oct 1998 – Dec 2000

• Executive Director, Global Economic Affairs, Wyeth Ayerst | Jul 1997 – Sep 1998

• Senior Director, Strategic Pricing, Wyeth Ayerst International | Dec 1994 – Jul 1997

• Manager, Business Development, Lederle International | Feb 1994 – Dec 1994

• General Manager, Lederle Netherlands | Sep 1992 – Feb 1994

• Business Unit Manager, Hospital Unit | Jul 1991 – Sep 1992

• Business Unit Manager, Office Unit | Dec 1990 – Jul 1991

• Field Sales Manager, Hospital Team | Oct 1989 – Dec 1990

• Medical Representative, Lederle Laboratories | Feb 1989 – Oct 1989

• Associate Product Manager, Lederle International Division | Aug 1988 – Feb 1989

• Recognized global expert in drug pricing; author of The Price of Global Health, widely referenced in the industry

• Built and led multiple global pricing and economic affairs organizations across top pharmaceutical companies

• Guided value, pricing, and reimbursement strategies for major drug launches worldwide

• Served as expert witness on pharmaceutical pricing and access matters

• Advised executives and boards across biopharma on evidence development and payer strategy

• Led large global consulting practice delivering pricing, access, and value insights to top pharmaceutical firms

• Restored profitability and resolved major reimbursement disputes in leadership roles

• Participated in WHO/WTO working group on differential drug pricing

• MBA, Finance & International Business, University of California, Graduate School of Management, Los Angeles | 1986–1988

• MS, Aeronautical Engineering, Delft University of Technology | 1976–1982

• Advanced global understanding of pharmaceutical pricing through executive leadership, consulting, and published thought leadership

• Influenced pricing policy and payer evidence strategies across top global biopharmaceutical organizations

• Strengthened industry knowledge through expert witness testimony and strategic advisory engagements

• Improved global access planning and value communication practices through a blend of corporate and consulting leadership

• Supported research-driven nonprofits contributing to Alzheimer’s and related disease research advancements